New Delhi: Going by the results from the early-stage clinical trials of Sputnik, the Russia registered world’s first COVID-19 vaccine, there is hope. The trials show that formulations of a two-part vaccine have a good safety profile with no serious adverse events detected over 42 days.
The results were published in ‘The Lancet’. The trials also confirmed that the vaccine induces antibody responses in all participants within 21 days, reported The New Indian Express (TNIE).
The Russian government is keen to get the vaccine tried in India as part of the phase 3 trial. It also wants Indian manufacturers to mass-produce the vaccine.
Limitations in the research
TNIE quoted researchers as saying that more research is needed to evaluate the vaccine in different populations, including older age groups, individuals with underlying medical conditions, and people in at-risk groups.
Nasty Surprise For Fans In Bangalore Team India never fails to deliver the occasional nasty…
Bargarh: Hrusikesh Bhoi, popular for his iconic role of Kansa in Bargarh’s Dhanu Jatra, has…
New Delhi: Canadian Prime Minister Justine Trudeau took to X to mark the sixth anniversary…
New Delhi: Israel on Thursday killed Hamas chief Yahya Sinwar in a Gaza operation. In…
New Delhi/Bhubaneswar: Three IAS officers, including Reghu G of Odisha cadre, have been shifted to…
Kolkata: A massive fire broke out at Sealdah ESI Hospital here on Friday morning. According…
New Delhi: The Enforcement Directorate Guwahati questioned actor Tamannaah Bhatia on Thursday in connection with…
Bhubaneswar: Days after the road rage incident involving an Army officer and his fiancee, a…